Response to Degarelix After Resistance to Leuprolide in a Patient With Metastatic Prostate Cancer

J Adv Pract Oncol 2012;3:299–303 Androgen-deprivation therapy (ADT) is a common treatment for prostate cancer, as the androgen receptor (AR) plays a role in the development of this malignancy. Androgen-deprivation therapy agents can be classified as gonadotropin-releasing hormone (GnRH) agonists or GnRH antagonists. The most common GnRH agents in use are the GnRH agonists. However, these agents have been associated with concerns related to periodic increases in testosterone (Van Poppel & Klotz, 2012). Because of these issues, increasing attention is being paid to the use of GnRH antagonists in ADT. In this article, we will first review the mechanism of action of the GnRH agonists and antagonists. Subsequently, we will present a discussion of the case study found on page 300. We conclude the article with clinical implications for GnRH agonist and antagonist use for oncology advanced practitioners who treat patients with prostate cancer in their practices.

• Publication year

  2012

• Venue

  Journal of the Advanced Practitioner in Oncology

• Publication date

  2012-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.6004/JADPRO.2012.3.5.3PMID 25031959PMCID 4093351
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A switch from GnRH agonist to GnRH antagonist in castration-resistant prostate cancer patients leads to a low response rate on PSA

  2013cited by this paper
• A rapid PSA half-life following docetaxel chemotherapy is associated with improved survival in hormone refractory prostate cancer.

  2013cited by this paper
• Gonadotropin‐releasing hormone: An update review of the antagonists versus agonists

  2012cited by this paper
• Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide

  2012cited by this paper
• Response to degarelix after resistance to luteinizing hormone-releasing hormone agonist therapy for metastatic prostate cancer.

  2011cited by this paper
• New data, new paradigms for treating prostate cancer patients--VI: novel hormonal therapy approaches.

  2011cited by this paper
• Targeting the androgen receptor--theory and practice.

  2011cited by this paper
• A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.

  2011cited by this paper
• Combined androgen blockade for prostate cancer: Review of efficacy, safety and cost‐effectiveness

  2011cited by this paper
• Redefining hormone resistance in prostate cancer

  2010cited by this paper
• Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics.

  2010cited by this paper
• Current management of castrate-resistant prostate cancer.

  2010cited by this paper
• Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12‐month, comparative, phase III study

  2009cited by this paper
• Prostate-specific antigen half-life: a new predictor of progression-free survival and overall survival in Chinese prostate cancer patients.

  2009cited by this paper
• A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America.

  2008cited by this paper
• The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancer

  2008cited by this paper
• Testosterone surge: rationale for gonadotropin-releasing hormone blockers?

  2008cited by this paper
• Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.

  2007cited by this paper
• Rapid Suppression of Plasma Testosterone Levels and Tumor Growth in the Dunning Rat Model Treated with Degarelix, a New Gonadotropin-Releasing Hormone Antagonist

  2007cited by this paper
• Molecular determinants of resistance to antiandrogen therapy

  2004cited by this paper
• Flare Associated with LHRH-Agonist Therapy.

  2001cited by this paper
• THE JOURNAL OF UROLOGY.

  year unknowncited by this paper

• No citing papers are available for this paper.